Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2001

View Archived Issues

Novel contrast agent detects coronary stenosis and myocardial viability

NT-proBNP offers promise as a diagnostic agent for heart failure

Xoma reports company highlights

Beyond ACE-I in Heart Failure Treatment -- Internet Webcast available to Daily Essentials readers

FDA denies approval of BMS's UFT capsules + leucovorin tablets

Sildenafil shows good cardiovascular safety and beneficial effects on exercise capacity

Takeda selects numerous targets in genomics alliance with Human Genome Sciences

Pfizer to terminate agreement with Unigene for oral calcitonin

NeoTherapeutics to evaluate Neotrofin in spinal cord injury patients

FDA places M-Vax and O-Vax on clinical hold

Glivec granted priority review status in U.S.

Amylin and Alkermes initiate study of long-acting formulation of AC-2993

Phase II study of decitabine as MDS treatment enrolling patients

Clopidogrel a major advance in the management of acute coronary syndrome according to CURE

ReoPro has consistent benefits in reducing the risk of death when combined with PCI

Integrilin plus half-dose TNKase effectively opens occluded arteries in heart attack patients

Treatment with niacin may safely reduce cardiovascular risk factors in diabetic patients

AACR news: ImClone designs novel protein-based melanoma vaccine

Anti-Infective Drugs Advisory Committee to review NDA filed for Ketek in late April

Photodynamic therapy with MV-6401 for selectively destroying tumor vasculature

Pharmacokinetic, toxicity data presented for VNP-40101M this week to AACR

Tumor growth completely suppressed by natural biological response modifier

Combinations of NSAID and EGF receptor kinase inhibitor for colonic polyps

Use of rAAV for preventing restenosis described in recent patent

Caspase inhibitors emerge from Vertex R&D program

Leo presents improved vitamin D analogues for cancer, psoriasis

P&G describes new PGF analogues particularly useful in bone disorders

Chemokine receptor antagonists designed as part of joint Millennium/Kyowa Hakko program

Boehringer Ingelheim patents new series of factor Xa inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...